2. Signaling Pathways
  3. Immunology/Inflammation
  4. Complement System

Complement System

Complement System

Related Products

PDF 0.66 MB

The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.

The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P992482
    VIR-2482
    VIR-2482 is a monoclonal antibody targeting influenza A hemagglutinin (HA). VIR-2482 is generated by introducing LS mutations (M428L/N434S) into the Fc region of MEDI8852 (HY-P991446). VIR-2482 binds to the conserved HA stem epitope across all 18 influenza A HA subtypes, neutralizes a broad spectrum of H1N1 and H3N2 strains, binds to FcγRIIIa, FcγRIIa and C1q, and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. VIR-2482 reduces morbidity and mortality caused by seasonal influenza A strains and provides prophylactic protection in mice. VIR-2482 can be used in research related to influenza A disease.
    VIR-2482
  • HY-NP194B
    Cyclosporin A-KLH
    Cyclosporin A-KLH is a conjugate of Cyclosporin A (HY-B0579) and KLH. Cyclosporin A is an immunosuppressant which binds to the cyclophilin .
    Cyclosporin A-KLH
  • HY-183352
    BuChE-IN-23
    BuChE-IN-23 is an orally active, blood-brain barrier permeable butyrylcholinesterase (eqBuChE) inhibitor with an IC50 of 15.59 μM and a Ki of 29.33 μM. BuChE-IN-23 exhibits an IC50 of 38.65 μM against hBuChE and shows selectivity for butyrylcholinesterase over acetylcholinesterase. BuChE-IN-23 inhibits LPS (HY-D1056)-induced nitric oxide production, attenuates hippocampal glial cell activation and neuroinflammation, suppresses the TLR4/p38 MAPK signaling pathway, and regulates the IL-1β/C3-mediated microglia-astrocyte inflammatory axis. BuChE-IN-23 can be used for the research of Alzheimer's disease.
    BuChE-IN-23
  • HY-17627S1
    Avacopan-d4
    		Inhibitor
    Avacopan-d4 (CCX168-d4) is the deuterium labeled Avacopan (HY-17627). Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
    Avacopan-d<sub>4</sub>
  • HY-P1345B
    [DArg10, DAla20] TLQP-21
    		Agonist
    [DArg10, DAla20] TLQP-21, TLQP-21 (HY-P1345) analogue, is a C3aR agonist (EC50: 87 nM for β-arrestin recruitment). [DArg10, DAla20] TLQP-21 elicits calcium influx. [DArg10, DAla20] TLQP-21 slightly but not significantly potentiates adrenergic-induced lipolysis. [DArg10, DAla20] TLQP-21 can be used in the research of inflammatory diseases, metabolic disorders, and neurological conditions.
    [DArg10, DAla20] TLQP-21
  • HY-NP0194B
    C1q Protein (rabbit)
    C1q Protein (rabbit) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rabbit) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
    and non-immune cells. C1q Protein (rabbit) can be used for the research of mutiple disease.
    C1q Protein (rabbit)
  • HY-177388
    Factor B-IN-6
    		Inhibitor
    Factor B-IN-6 is an orally active Factor B inhibitor. Factor B-IN-6 exhibits significant inhibitory activity against activation of the human serum serotonin pathway. Factor B-IN-6 can improve the severity of renal lesions and renal function, and reduce urinary protein in animal models. Factor B-IN-6 is useful for kidney disease research.
    Factor B-IN-6
  • HY-P4971
    C5a Anaphylatoxin (human)
    		Modulator
    C5a Anaphylatoxin (human) is a pro-inflammatory peptide and a leukocyte chemoattractant. C5a Anaphylatoxin (human) can be used to study inflammation and immunity, such as allergic asthma.
    C5a Anaphylatoxin (human)
  • HY-P991922
    AKIR001
    		Inhibitor
    AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [177Lu] radiolabeled AKIR001, namely [177Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma.
    AKIR001
  • HY-183414
    C5aR antagonist-1
    		Antagonist
    C5aR antagonist-1 is a potent C5aR antagonist with an IC50 of < 5 nM. C5aR antagonist-1 is applicable to the research of crescentic and necrotizing glomerular lesions.
    C5aR antagonist-1
  • HY-P3502A
    Zilucoplan TFA
    		Inhibitor
    Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM).
    Zilucoplan TFA
  • HY-P10995
    TAT-327
    		Inhibitor
    TAT-327 is cell-penetrating peptide. TAT-327 selectively inserts into cancer cell membranes and shows potent antitumor activity. TAT-327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. TAT-327 significantly inhibits tumor growth in HT-29 xenograft mcie models.
    TAT-327
  • HY-P3204A
    POT-4 TFA
    		Inhibitor
    POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research.
    POT-4 TFA
  • HY-P992456
    SAR-443809
    		Inhibitor
    SAR-443809 is a selective alternative complement system inhibitor and monoclonal antibody targeting complement factor Bb. SAR-443809 blocks the cleavage of C3 and factor B by selectively binding to the activated form of factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for the research of hematological and renal disorders mediated by abnormal alternative complement pathway.
    SAR-443809
  • HY-174913
    Factor B-IN-5
    		Inhibitor
    Factor B-IN-5 is an orally active complement factor B (CFB) inhibitor. Factor B-IN-5 alleviates kidney damage in diabetes nephropathy by inhibiting the over activation of complement system and improving mitochondrial function. Factor B-IN-5 can improve renal tubulointerstitial inflammation and fibrosis. Factor B-IN-5 can be used for research on diabetic nephropathy.
    Factor B-IN-5
  • HY-200854
    Iptacopan hydrochloride hydrate
    		Inhibitor
    Iptacopan (LNP023) hydrochloride hydrate is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride hydrate exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride hydrate can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G).
    Iptacopan hydrochloride hydrate
  • HY-147585
    C5aR-IN-1
    C5aR-IN-1 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-1 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 47).
    C5aR-IN-1
  • HY-W371164
    C1s-IN-1
    		Inhibitor
    C1s-IN-1 (compound A1) is a selective and competitive inhibitor of C1s. C1s-IN-1 binds directly to C1s with a Kd of 9.8 μM.
    C1s-IN-1
  • HY-147587
    C5aR-IN-3
    C5aR-IN-3 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-3 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 89).
    C5aR-IN-3
  • HY-P991329
    ASP-1948
    		Inhibitor
    ASP-1948 is a human monoclonal antibody (mAb) targeting NRP1/VEGF165R/CD34. ASP-1948 reverses the suppressive effects of regulatory T cells. ASP-1948 can be used in solid tumors research.
    ASP-1948
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity